Background: Choroid plexus tumors are rare neoplasms that primarily occur in children. The use of the SEER (Surveillance, Epidemiology and End Results) database allows for the analysis of the relationship between prognostic factors and survival. Methods: We analyzed the SEER database to select pediatric patients (<18 years old) with histologically confirmed diagnoses of choroid plexus papillomas (CPP; WHO Grade 0), atypical CPP (WHO Grade I) and choroid plexus carcinomas (CPC; WHO grade III). In univariate and multivariate analysis, we analyzed the relationship between demographic (age, gender, race, date of diagnosis) and treatment factors (extent of surgical resection, use of adjuvant radiation) on survival. Results: Overall, 168 pediatric subjects with choroid plexus tumors were identified as follows: 75 cases of CPP, 12 cases of atypical CPP and 81 cases of CPC. The median follow-up time was 3.5 years for CPP and 7.7 years for CPC. The median age at diagnosis was 4 years for CPP (10-90th percentile 0-16 years) and 1 year for CPC (10-90th percentile 0-10 years). In univariate regression analysis, CPC histology (β = -3.2, 95% confidence interval, CI -4.8 to -1.5, p < 0.001) was significantly associated with younger age at diagnosis in comparison to CPP. The mean tumor size was 3.7 cm for CPP and 6.0 cm for CPC (p < 0.001). A higher-grade tumor was associated with significantly increased mortality (hazard ratio, HR = 28.90, 95% CI 3.94-211.83, p = 0.001). Overall survival at 5 years was 98.7% for CPP and 58.5% for CPC (p < 0.001). Among those patients with CPC, gross total resection (GTR) was associated with a significantly lower mortality (HR = 0.21, 95% CI 0.07-0.66, p = 0.007). Overall survival at 5 years was 70.9% after GTR, significantly better than 35.9% after subtotal resection (p = 0.012) and 30% after no surgery (p = 0.003). Radiation treatment was not found to confer a survival benefit in CPC. No demographic characteristics (age, sex, race, date of diagnosis) were significantly associated with mortality. Conclusions: Analysis of a pediatric cohort of choroid plexus tumors in children in the SEER database shows that tumor grade is predictive of survival. In cases of CPC, the extent of surgical resection, especially GTR, is significantly associated with increased survival. Radiation did not confer survival benefit.

Keywords:
Choroid plexus tumor, Choroid plexus carcinoma, Choroid plexus papilloma, SEER database, Pediatric
1.
Gupta N: Choroid plexus tumors in children. Neurosurg Clin N Am 2003;14:621-631.
2.
Laurence KM: The biology of choroid plexus papilloma in infancy and childhood. Acta Neurochir (Wien) 1979;50:79-90.
3.
Ogiwara H, Dipatri AJ Jr, Alden TD, Bowman RM, Tomita T: Choroid plexus tumors in pediatric patients. Br J Neurosurg 2012;26:32-37.
4.
Wolff JE, Sajedi M, Brant R, Coppes MJ, Egeler RM: Choroid plexus tumours. Br J Cancer 2002;87:1086-1091.
5.
Berger C, Thiesse P, Lellouch-Tubiana A, Kalifa C, Pierre-Kahn A, Bouffet E: Choroid plexus carcinomas in childhood: clinical features and prognostic factors. Neurosurgery 1998;42:470-475.
6.
Ellenbogen RG, Winston KR, Kupsky WJ: Tumors of the choroid plexus in children. Neurosurgery 1989;25:327-335.
7.
Packer RJ, Perilongo G, Johnson D, Sutton LN, Vezina G, Zimmerman RA, Ryan J, Reaman G, Schut L: Choroid plexus carcinoma of childhood. Cancer 1992;69:580-585.
8.
St Clair SK, Humphreys RP, Pillay PK, Hoffman HJ, Blaser SI, Becker LE: Current management of choroid plexus carcinoma in children. Pediatr Neurosurg 1991;17:225-233.
9.
Sun MZ, Ivan ME, Clark AJ, Oh MC, Delance AR, Oh T, Safaee M, Kaur G, Bloch O, Molinaro A, Gupta N, Parsa AT: Gross total resection improves overall survival in children with choroid plexus carcinoma. J Neurooncol 2014;116:179-185.
10.
Lozier AP, Arbaje YM, Scheithauer BW: Supratentorial, extraventricular choroid plexus carcinoma in an adult: case report. Neurosurgery 2009;65:E816-E817.
11.
Wolff JE, Sajedi M, Coppes MJ, Anderson RA, Egeler RM: Radiation therapy and survival in choroid plexus carcinoma. Lancet 1999;353:2126.
12.
Surgeons ACo: FORDS: Facility Oncology Registry Data Standards. Chicago, Commission on Cancer, 2002.
13.
Lam S, Lin Y, Melkonian S: Analysis of risk factors and survival in pediatric high-grade spinal cord astrocytoma: a population-based study. Pediatr Neurosurg 2012;48:299-305.
14.
Wong AP, Dahdaleh NS, Fessler RG, Melkonian SC, Lin Y, Smith ZA, Lam SK: Risk factors and long-term survival in adult patients with primary malignant spinal cord astrocytomas. J Neurooncol 2013;115:493-503.
15.
Adams H, Avendano J, Raza SM, Gokaslan ZL, Jallo GI, Quinones-Hinojosa A: Prognostic factors and survival in primary malignant astrocytomas of the spinal cord: a population-based analysis from 1973 to 2007. Spine (Phila Pa 1976) 2012;37:E727-E735.
16.
Clark TG, Bradburn MJ, Love SB, Altman DG: Survival analysis. Part I. Basic concepts and first analyses. Br J Cancer 2003;89:232-238.
17.
Sampath S, Nitin G, Yasha TC, Chandramouli BA, Devi BI, Kovoor JM: Does choroid plexus tumour differ with age? Br J Neurosurg 2008;22:373-388.
18.
Due-Tonnessen B, Helseth E, Skullerud K, Lundar T: Choroid plexus tumors in children and young adults: report of 16 consecutive cases. Childs Nerv Syst 2001;17:252-256.
19.
Tomita T, McLone DG, Flannery AM: Choroid plexus papillomas of neonates, infants and children. Pediatr Neurosci 1988;14:23-30.
20.
Steichen-Gersdorf E, Trawoger R, Duba HC, Mayr U, Felber S, Utermann G: Hypomelanosis of Ito in a girl with plexus papilloma and translocation (X;17). Hum Genet 1993;90:611-613.
21.
Zajac V, Kirchhoff T, Levy ER, Horsley SW, Miller A, Steichen-Gersdorf E, Monaco AP: Characterisation of X;17(q12;p13) translocation breakpoints in a female patient with hypomelanosis of Ito and choroid plexus papilloma. Eur J Hum Genet 1997;5:61-68.
22.
Mauffrey C: Paediatric brainstem gliomas: prognostic factors and management. J Clin Neurosci 2006;13:431-437.
23.
Qaddoumi I, Sultan I, Gajjar A: Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the surveillance, epidemiology, and end results database. Cancer 2009;115:5761-5770.
24.
Gopal P, Parker JR, Debski R, Parker JC Jr: Choroid plexus carcinoma. Arch Pathol Lab Med 2008;132:1350-1354.
25.
Lafay-Cousin L, Keene D, Carret AS, Fryer C, Brossard J, Crooks B, Eisenstat D, Johnston D, Larouche V, Silva M, Wilson B, Zelcer S, Bartels U, Bouffet E: Choroid plexus tumors in children less than 36 months: the Canadian Pediatric Brain Tumor Consortium (CPBTC) experience. Childs Nerv Syst 2011;27:259-264.
26.
Meyers SP, Khademian ZP, Chuang SH, Pollack IF, Korones DN, Zimmerman RA: Choroid plexus carcinomas in children: MRI features and patient outcomes. Neuroradiology 2004;46:770-780.
27.
Duffner PK, Kun LE, Burger PC, Horowitz ME, Cohen ME, Sanford RA, Krischer JP, Mulhern RK, James HE, Rekate HL, et al: Postoperative chemotherapy and delayed radiation in infants and very young children with choroid plexus carcinomas. The Pediatric Oncology Group. Pediatr Neurosurg 1995;22:189-196.
28.
Souweidane MM, Johnson JH Jr, Lis E: Volumetric reduction of a choroid plexus carcinoma using preoperative chemotherapy. J Neurooncol 1999;43:167-171.
29.
Greenberg ML: Chemotherapy of choroid plexus carcinoma. Childs Nerv Syst 1999;15:571-577.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.